“Toxicology studies of ocrelizumab were conducted in cynomolgus monkey, the only pharmacologically relevant species”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
Why that species
Binds CD20 in humans and nonhuman primates, not in rodents
“Ocrelizumab specifically binds CD20 in humans and nonhuman primates. It does not bind CD20 in rodents. Therefore, cynomolgus monkey was selected as the relevant species for nonclinical investigation.”
✓ VerifiedFDA pharmacology/toxicology review, p. 23Source ↗
Surrogate molecule
No surrogate; the clinical antibody was tested in cynomolgus monkeys
“Toxicology studies of ocrelizumab were conducted in cynomolgus monkey, the only pharmacologically relevant species”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗